title: Relapsed and refractory Hodgkin's lymphoma: new avenues?
abstract: Relapse or progression following therapy for Hodgkin's lymphoma occurs in 10% to 60% of patients depending on initial clinical stage. Patterns of failure in advanced disease determine prognosis of salvage therapy. Progression or early relapse after less than 12 months requires intensive salvage therapy. Only late, isolated, asymptomatic relapse, which occurs in less than 25% of those relapsing from systemic therapy, can be treated with conventional-dose chemotherapy with or without radiation. Overall about 40% to 50% of relapses from advanced disease can be salvaged with higher percentages for patients relapsing from early stage disease.
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. george_canellos@dfci.harvard.edu
authors.forename: George P
authors.initials: GP
authors.lastname: Canellos
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D007155:Immunologic Factors